Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2015

View Archived Issues

Takeda synthesizes tetrahydronaphthalene Raf inhibitors with selectivity over hERG

University of Utah patents re-engineered tumor suppressor p53

Fixed Phage reports bacteriophage-based antibacterials

LMG-324 begins first-in-human study for AMD

Novel FFAR4 agonist shows glucose-lowering effect in vivo

Work at Merck & Co. leads to identification of mineralcorticoid receptor antagonists

Challenge award supports NantKwest's natural killer cell-based therapy for prostate cancer

Celgene completes acquisition of Receptos

Onconova Therapeutics files European CTAs for global phase III trial of rigosertib

Purdue Pharma discloses Nav1.7 channel blockers

Lilly patents GPR142 agonists

Incyte divulges LSD1 inhibitors

Celyad and Medisun sign license agreement for C-Cure in Greater China

Merck & Co. introduces cathepsin K inhibitors

Bayer and DKFZ present inhibitors of mutated IDH1

BMS and QIMR Berghofer Medical Research Institute partner in immuno-oncology

Cryogel injectable biomaterial provides novel cancer vaccine platform

FDA grants priority review to Telesta's BLA for MCNA

FDA approves Aptiom as monotherapy for partial-onset seizures

Yervoy Injection launched in Japan

Novartis launches Farydak capsules for multiple myeloma in Japan

Nintedanib launched in Japan for the treatment of idiopathic pulmonary fibrosis

Three-protein panel can detect pancreatic cancer from urine samples

Gilead launches Harvoni in Japan for the treatment of genotype 1 chronic HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...